Two landmark trials give CVD outcomes for diabetes drugs
Results for linagliptin and dapagliflozin
14th November 2018
By Clare Pain
Two trials looking at cardiovascular and renal outcomes in patients on therapy for type 2 diabetes will help doctors tailor treatment better to the patient, a diabetes specialist says.
In the CARMELINA international randomised controlled trial, nearly 7000 patients with type 2 diabetes, high cardiovascular risk and high renal risk, were randomised to the dipeptidyl peptidase 4 (DPP-4) inhibitor linagliptin 5mg once-a-day or to placebo.
Over a median follow-up of 2.2 years, linagliptin (Trajenta, Boehringer Ingelheim) was not inferior to placebo for cardiovascular outcomes